Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2026
Effect of salbutamol during one-lung ventilation in patients with chronic obstructive pulmonary disease: a randomized controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oh Young Jun, Kim Namo, Choo Hyeonju, Lee Kyuho
Аннотация
PURPOSE: Ventilation-perfusion mismatch during one-lung ventilation (OLV) for thoracic surgery increases the risk of hypoxemia. Salbutamol may selectively dilate pulmonary vessels and enhance perfusion of the ventilated lung. We sought to investigate whether selective salbutamol nebulization to the ventilated lung during OLV improves gas exchange and respiratory mechanics in patients with chronic obstructive pulmonary disease (COPD).
METHODS: In this prospective randomized controlled trial, we randomly allocated 90 patients scheduled for lung resection to receive salbutamol or placebo nebulization 30 min after OLV initiation and analyzed 82 patients (41 per group). The primary endpoint was the change in the partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2/FIO2) after nebulization. Secondary outcomes included other gas exchange and respiratory mechanics indices, hemodynamic variables, and perioperative complications.
RESULTS: Compared with placebo, salbutamol increased PaO2/FIO2 (mean difference, 26; 95% confidence interval [CI], 0 to 53; P = 0.03) and decreased alveolar dead space (mean difference, -1.7; 95% CI, -4.3 to -0.1; P = 0.04) as well as serum potassium (mean difference, -0.2; 95% CI, -0.4 to 0.0; P = 0.01). Heart rate rose transiently without arrhythmia. In a subgroup of patients who had received preoperative inhaler therapy, no between-group differences were observed.
CONCLUSIONS: Selective salbutamol nebulization during OLV improved oxygenation and respiratory mechanics without serious adverse events, and it may be considered as an adjunctive option for the management of intraoperative hypoxemia in patients with COPD. The lack of benefit among patients who received preoperative inhaler therapy suggests that intraoperative selective one-lung nebulization may be more advantageous than preoperative two-lung nebulization.
STUDY REGISTRATION: ClinicalTrials.gov ( NCT05914285 ); first submitted 13 June 2023.
METHODS: In this prospective randomized controlled trial, we randomly allocated 90 patients scheduled for lung resection to receive salbutamol or placebo nebulization 30 min after OLV initiation and analyzed 82 patients (41 per group). The primary endpoint was the change in the partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2/FIO2) after nebulization. Secondary outcomes included other gas exchange and respiratory mechanics indices, hemodynamic variables, and perioperative complications.
RESULTS: Compared with placebo, salbutamol increased PaO2/FIO2 (mean difference, 26; 95% confidence interval [CI], 0 to 53; P = 0.03) and decreased alveolar dead space (mean difference, -1.7; 95% CI, -4.3 to -0.1; P = 0.04) as well as serum potassium (mean difference, -0.2; 95% CI, -0.4 to 0.0; P = 0.01). Heart rate rose transiently without arrhythmia. In a subgroup of patients who had received preoperative inhaler therapy, no between-group differences were observed.
CONCLUSIONS: Selective salbutamol nebulization during OLV improved oxygenation and respiratory mechanics without serious adverse events, and it may be considered as an adjunctive option for the management of intraoperative hypoxemia in patients with COPD. The lack of benefit among patients who received preoperative inhaler therapy suggests that intraoperative selective one-lung nebulization may be more advantageous than preoperative two-lung nebulization.
STUDY REGISTRATION: ClinicalTrials.gov ( NCT05914285 ); first submitted 13 June 2023.